Diagnostic value of serum tumor markers evaluation for adnexal masses

[1] Rivas-Corchado LM, González-Geroniz M, Hernández-Herrera RJ. Epidemiological profile of ovarian cancer. Ginecol Obstet Mex 2011; 79:558–564 Search in Google Scholar

[2] Sehouli J, Henrich W, Braicu I, Lichtenegger W. Preoperative diagnostics in ovarian cancer. What do we really need? Gynäkologe 2006; 39:428–437 http://dx.doi.org/10.1007/s00129-006-1839-910.1007/s00129-006-1839-9Search in Google Scholar

[3] Ameye L, Valentin L, Testa A.C, Van Holsbeke C, Domali E, Van Huffel S, et all. A scoring system to differentiate malignant from benign masses in specific ultrasound-based subgroups of adnexal tumors. Ultrasound Obstet Gynecol 2009; 33:92–101 http://dx.doi.org/10.1002/uog.627310.1002/uog.6273Search in Google Scholar

[4] American College of Obstetricians and Gynecologists. Committee Opinion No. 477. The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117:742–746 http://dx.doi.org/10.1097/AOG.0b013e31821477db10.1097/AOG.0b013e31821477dbSearch in Google Scholar

[5] Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et all. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10:327–340 http://dx.doi.org/10.1016/S1470-2045(09)70026-910.1016/S1470-2045(09)70026-9Search in Google Scholar

[6] Joyner AB, Runowicz CD. Ovarian cancer screening and early detection. Womens Health 2009; 5:693–699 Search in Google Scholar

[7] Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC Jr, et all. Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol 2010; 31:209–215 http://dx.doi.org/10.1007/s13277-010-0032-x10.1007/s13277-010-0032-xSearch in Google Scholar PubMed

[8] Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, et all. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008; 112:2202–2210 http://dx.doi.org/10.1002/cncr.2339010.1002/cncr.23390Search in Google Scholar PubMed

[9] Terzic M, Dotlic J, Likic I, Ladjevic N, Brndusic N, Arsenovic N, Maricic S, Mihailovic T, Andrijasevic S. Current diagnostic approach to patients with adnexal masses: Which tools are relevant in routine praxis ? Chin J Cancer Res 2012 DOI: 10.3978/j.issn.1000-9604.2013.01.01 Search in Google Scholar

[10] Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, et al. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 2010; 136:1079–1088 http://dx.doi.org/10.1007/s00432-009-0755-510.1007/s00432-009-0755-5Search in Google Scholar PubMed PubMed Central

[11] Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et all. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14:1065–1072 http://dx.doi.org/10.1158/1078-0432.CCR-07-156910.1158/1078-0432.CCR-07-1569Search in Google Scholar PubMed

[12] Chia YN, Marsden DE, Robertson G, Hacker NF. Triage of ovarian masses. Aust NZ J Obstet Gynaecol 2008; 48: 322–328 http://dx.doi.org/10.1111/j.1479-828X.2008.00825.x10.1111/j.1479-828X.2008.00825.xSearch in Google Scholar PubMed

[13] Rong-Huan H, Wei-Miao Y, Li-Yan W, Yu-Yan M. Highly elevated serum CA-125 levels in patients with non-malignant gynecological diseases. Arch Gynecol Obstet 2011; 283:S107–S110 http://dx.doi.org/10.1007/s00404-010-1717-510.1007/s00404-010-1717-5Search in Google Scholar PubMed

[14] Vorgias G, Iavazzo C, Savvopoulos P, Myriokefalitaki E, Katsoulis M, Kalinoglou N, et all. Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol Oncol 2009; 112:11–15 http://dx.doi.org/10.1016/j.ygyno.2008.09.02010.1016/j.ygyno.2008.09.020Search in Google Scholar

[15] Terzic M, Dotlic J, Likic Ladjevic I, Atanackovic J, Ladjevic N. Evaluation of the risk malignancy index diagnostic value in patients with adnexal masses. Vojnosanit Pregl 2011; 68:589–593 http://dx.doi.org/10.2298/VSP1107589T10.2298/VSP1107589TSearch in Google Scholar

[16] Dotlic J, Terzic M, Likic I, Atanackovic J, Ladjevic N. Evaluation of adnexal masses: correlation of clinical stage, ultrasound and hystopathological findings. Vojnosanit Pregl 2011; 68: 861–866 http://dx.doi.org/10.2298/VSP1110861D10.2298/VSP1110861DSearch in Google Scholar

[17] Van Calster B, Valentin L, Van Holsbeke C, Zhang J, Jurkovic D, Lissoni AA, et all. A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study. Cancer Epidemiol Biomarkers Prev 2011; 20:2420–2422 http://dx.doi.org/10.1158/1055-9965.EPI-11-042210.1158/1055-9965.EPI-11-0422Search in Google Scholar

[18] Langmar Z, Nemeth M, Vlesko G, Kiraly M, Hornyak L, Bosze P. HE4-a novel promising serum marker in the diagnosis of ovarian carcinoma. Eur J Gynaecol Oncol 2011; 32:605–610 Search in Google Scholar

[19] Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol. 2012 DOI: 10.1007/s13277-012-0381-8 10.1007/s13277-012-0381-8Search in Google Scholar

[20] Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010; 31:113–119 http://dx.doi.org/10.1007/s13277-009-0015-y10.1007/s13277-009-0015-ySearch in Google Scholar

[21] Zheng H, Gao Y. Serum HE4 as a Useful Biomarker in Discriminating Ovarian Cancer From Benign Pelvic Disease. Int J Gynecol Cancer. 2012 DOI: 10.1097/IGC.0b013e318249bee7 10.1097/IGC.0b013e318249bee7Search in Google Scholar

[22] Ayhan A, Guven S, Guven ES, Kucukali T. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand. 2007; 86:484–90 http://dx.doi.org/10.1080/0001634070122613810.1080/00016340701226138Search in Google Scholar

[23] Ugur MG, Ozturk E, Balat O, Dikensoy E, Teke S, Aydin A. Do high levels of CA 19-9 in women with mature cystic teratomas of the ovary warrant further evaluation? Eur J Gynaecol Oncol. 2012; 33:207–10 Search in Google Scholar

[24] van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001; 92:2837–2844 http://dx.doi.org/10.1002/1097-0142(20011201)92:11<2837::AID-CNCR10093>3.0.CO;2-510.1002/1097-0142(20011201)92:11<2837::AID-CNCR10093>3.0.CO;2-5Search in Google Scholar

[25] Mabrouk M, Elmakky A, Caramelli E, Farina A, Mignemi G, Venturoli S, et al. Performance of peripheral (serum and molecular) blood markers for diagnosis of endometriosis. Arch Gynecol Obstet. 2011 DOI: 10.1007/s00404-011-2122-2124 Search in Google Scholar

[26] Sørensen SS, Mosgaard BJ. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull. 2011; 58:A4331 Search in Google Scholar